FSFatima Smih

Fatima Smih

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fatima Smih has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Annie Turkieh

    Inserm, CHU Lille, Institut Pasteur de Lille, U1167‐RID‐AGE Université de Lille Lille France

    4 shared publications
  • Philippe Rouet

    LA Maison de la MItochondrie (LAMMI), Obesity and heart failure: molecular and clinical investigations, UMR CNRS 5288, 1 Avenue Jean Poulhes, BP 84225, 31432 Toulouse cedex 4, France; INI-CRCT F-CRIN, GREAT Networks, France

    4 shared publications
  • François Koukoui

    Inserm U1048, équipe 7, obésité et insuffisance cardiaque : approches moléculaires et cliniques, BP 84225, 1, avenue Jean Poulhès, 31432 Toulouse Cedex 4, France

    3 shared publications
  • Michel Galinier

    Department of Cardiology, Rangueil University Hospital, Toulouse, France

    3 shared publications
  • Romain Harmancey

    Inserm U1048, équipe 7, obésité et insuffisance cardiaque : approches moléculaires et cliniques, BP 84225, 1, avenue Jean Poulhès, 31432 Toulouse Cedex 4, France

    3 shared publications
  • Camille Dambrin

    Inserm U1048, équipe 7, obésité et insuffisance cardiaque : approches moléculaires et cliniques, BP 84225, 1, avenue Jean Poulhès, 31432 Toulouse Cedex 4, France

    2 shared publications

Latest Publications

  • Open Access

    APOO, une protéine mitochondriale impliquée dans la cardiomyopathie diabétique

    by Philippe Rouet, Romain Harmancey, Annie Turkieh, Céline Caubère, Manon Barutaut, François Koukoui, Camille Dambrin, Michel Galinier, Fatima Smih


  • Open Access

    13C metabolic flux analysis shows that resistin impairs the metabolic response to insulin in L6E9 myotubes

    by Shirley Guzmán, Silvia Marin, Anibal Miranda, Vitaly A Selivanov, Josep J Centelles, Romain Harmancey, Fatima Smih, Annie Turkieh, Yves Durocher, Antonio Zorzano, et al.

    It has been suggested that the adipokine resistin links obesity and insulin resistance, although how resistin acts on muscle metabolism is controversial. We aimed to quantitatively analyse the effects of resistin on the glucose metabolic flux profile and on insulin response in L6E9 myotubes at the metabolic level using a tracer-based metabolomic approach and our in-house developed software, Isodyn.


  • Open Access

    Apolipoprotein O is mitochondrial and promotes lipotoxicity in heart

    by Annie Turkieh, Céline Caubère, Manon Barutaut, Franck Desmoulin, Romain Harmancey, Michel Galinier, Matthieu Berry, Camille Dambrin, Carlo Polidori, Louis Casteilla, et al.

    Diabetic cardiomyopathy is a secondary complication of diabetes with an unclear etiology. Based on a functional genomic evaluation of obesity-associated cardiac gene expression, we previously identified and cloned the gene encoding apolipoprotein O (APOO), which is overexpressed in hearts from diabetic patients. Here, we generated APOO-Tg mice, transgenic mouse lines that expresses physiological levels of human APOO in heart tissue. APOO-Tg mice fed a high-fat diet exhibited depressed ventricular function with reduced fractional shortening and ejection fraction, and myocardial sections from APOO-Tg mice revealed mitochondrial degenerative changes. In vivo fluorescent labeling and subcellular fractionation revealed that APOO localizes with mitochondria. Furthermore, APOO enhanced mitochondrial uncoupling and respiration, both of which were reduced by deletion of the N-terminus and by targeted knockdown of APOO. Consequently, fatty acid metabolism and ROS production were enhanced, leading to increased AMPK phosphorylation and Ppara and Pgc1a expression. Finally, we demonstrated that the APOO-induced cascade of events generates a mitochondrial metabolic sink whereby accumulation of lipotoxic byproducts leads to lipoapoptosis, loss of cardiac cells, and cardiomyopathy, mimicking the diabetic heart–associated metabolic phenotypes. Our data suggest that APOO represents a link between impaired mitochondrial function and cardiomyopathy onset, and targeting APOO-dependent metabolic remodeling has potential as a strategy to adjust heart metabolism and protect the myocardium from impaired contractility.


  • Open Access

    Blood Signature of Pre-Heart Failure: A Microarrays Study

    by Fatima Smih, Franck Desmoulin, Matthieu Berry, Annie Turkieh, Romain Harmancey, Jason Iacovoni, Charlotte Trouillet, Clement Delmas, Atul Pathak, Olivier Lairez, et al.

    The preclinical stage of systolic heart failure (HF), known as asymptomatic left ventricular dysfunction (ALVD), is diagnosed only by echocardiography, frequent in the general population and leads to a high risk of developing severe HF. Large scale screening for ALVD is a difficult task and represents a major unmet clinical challenge that requires the determination of ALVD biomarkers. 294 individuals were screened by echocardiography. We identified 9 ALVD cases out of 128 subjects with cardiovascular risk factors. White blood cell gene expression profiling was performed using pangenomic microarrays. Data were analyzed using principal component analysis (PCA) and Significant Analysis of Microarrays (SAM). To build an ALVD classifier model, we used the nearest centroid classification method (NCCM) with the ClaNC software package. Classification performance was determined using the leave-one-out cross-validation method. Blood transcriptome analysis provided a specific molecular signature for ALVD which defined a model based on 7 genes capable of discriminating ALVD cases. Analysis of an ALVD patients validation group demonstrated that these genes are accurate diagnostic predictors for ALVD with 87% accuracy and 100% precision. Furthermore, Receiver Operating Characteristic curves of expression levels confirmed that 6 out of 7 genes discriminate for left ventricular dysfunction classification. These targets could serve to enhance the ability to efficiently detect ALVD by general care practitioners to facilitate preemptive initiation of medical treatment preventing the development of HF.